Loading…
Reported covered position: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: TODD STRATEGY GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DH DIAGNOSTICS LLC via TODD STRATEGY GROUP
2026 · first_quarter · 1T
Issues related to diagnostic testing, antimicrobial resistance, Alzheimers. Oncology/Artificial Intelligence. Hepatitis C Funding. Issues related to tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Source: Senate LDA
| NOVO NORDISK, INC. |
| 14 |
| 2023–2026 |
| FOX CORPORATION | 13 | 2023–2026 |
| GENMAB | 13 | 2023–2026 |
| OSRX PHARMACEUTICALS | 13 | 2023–2025 |
| AMERICAN POLICY VENTURES ACTION | 12 | 2024–2026 |
| AMGEN, INC. | 12 | 2023–2026 |
| ILLUMINA, INC. | 12 | 2023–2026 |
| JOHNSON & JOHNSON SERVICES, INC. | 12 | 2023–2026 |
| MEDICAL COUNTERMEASURES COALITION | 12 | 2024–2026 |
| NOMI HEALTH, INC. | 12 | 2024–2026 |
| THE ORTHOFORUM | 12 | 2023–2026 |
| Alnylam Pharmaceuticals, Inc. | 11 | 2023–2026 |
| BIODESIX INC | 11 | 2023–2026 |
| BIOGEN, INC. | 11 | 2023–2026 |
| EXELIXIS, INC. | 11 | 2023–2026 |
| FERRING PHARMACEUTICALS, INC. | 11 | 2023–2025 |
| GENENTECH INC | 11 | 2023–2026 |
| GILEAD SCIENCES, INC. | 11 | 2023–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 11 | 2023–2026 |
| SIDECAR HEALTH | 11 | 2023–2026 |
| SIEMENS HEALTHINEERS | 11 | 2023–2026 |
| ALKERMES, INC. | 10 | 2023–2026 |
| DH DIAGNOSTICS, LLC | 10 | 2024–2026 |
| MYRIAD GENETICS INC | 10 | 2023–2026 |
| NOVARTIS, INC. | 10 | 2023–2026 |
| PUERTO RICO DEPARTMENT OF HEALTH | 10 | 2023–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 10 | 2023–2026 |
| ALEXION PHARMACEUTICALS, INC. | 9 | 2023–2025 |
| ASTELLAS PHARMA US, INC. | 9 | 2024–2026 |
| BAYER CORPORATION | 9 | 2024–2026 |
| ELI LILLY AND COMPANY | 9 | 2024–2026 |
| KALDEROS, INC. | 9 | 2024–2026 |
| MUTUAL OF OMAHA | 9 | 2024–2026 |
| EMD SERONO, INC. | 8 | 2023–2025 |
| HEALTH SUPPLY US LLC | 8 | 2023–2024 |
| HOSPICE COMPASSUS | 8 | 2023–2025 |
| U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER | 8 | 2024–2026 |
| ADULT VACCINE ACCESS COALITION | 7 | 2023–2024 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | 2023–2024 |
| GINKGO BIOSECURITY | 7 | 2023–2025 |
| MCKESSON CORPORATION | 7 | 2023–2025 |
| MERCK & CO., INC. | 7 | 2023–2025 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 7 | 2023–2025 |
| PFIZER, INC. | 7 | 2023–2026 |
| SOUTHWEST TRANSPLANT ALLIANCE | 7 | 2023–2025 |
| THE COALITION FOR 21ST CENTURY MEDICINE | 7 | 2023–2025 |
| AMERICAN COLLEGE OF RADIOLOGY | 6 | 2023–2025 |
| AVS BIO | 6 | 2024 |
| WINE & SPIRITS WHOLESALERS OF AMERICA | 6 | 2025–2026 |
| ALLIANCE FOR AMERICA'S PROMISE, INC. | 5 | 2025 |
| AMERICAN SOCIETY OF NEPHROLOGY | 5 | 2024–2025 |
| INSULET CORPORATION | 5 | 2025–2026 |
| NCTA - THE INTERNET & TELEVISION ASSOCIATION | 5 | 2025–2026 |
| VIAL HEALTH TECHNOLOGY INC. | 5 | 2025 |
| ASTRAZENECA PHARMACEUTICALS LP | 4 | 2025–2026 |
| CAREDX, INC. | 4 | 2025–2026 |
| Cepheid | 4 | 2023–2024 |
| EMD MILLIPORE | 4 | 2023 |
| FLEXCARE | 4 | 2024–2025 |
| LYNCH REGENERATIVE MEDICINE, LLC | 4 | 2025 |
| MED CLAIMS COMPLIANCE CORPORATION | 4 | 2024–2025 |
| CORMEDIX, INC. | 3 | 2023–2024 |
| VAXESS TECHNOLOGIES, INC | 3 | 2023–2024 |
| GRAIL, Inc. | 2 | 2023–2024 |
| HORIZON THERAPEUTICS USA, INC. | 2 | 2023 |
| KARIUS, INC. | 2 | 2023–2024 |
| UCB, INC. | 2 | 2023 |
Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act. Prescription drug pricing policy.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TODD STRATEGY GROUP
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues.
Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act. Prescription drug pricing policy.
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864: HELP Copays Act. General Medicare and Medicaid Issues.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: TODD STRATEGY GROUP
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: TODD STRATEGY GROUP
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Patents. Support for PREVAIL Act. Support for H.R.1574 - RESTORE Patent Rights Act of 2025.
Patents. Support for PREVAIL Act. Support for H.R.1574 - RESTORE Patent Rights Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
Drug Pricing. S.864 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
HELP Copays Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: TODD STRATEGY GROUP
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: TODD STRATEGY GROUP
Issues related to oncology and multi cancer early detection, including diagnostics and screening. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2026 · first_quarter · 1T
Tax policy related to qualified business investment tax credit.
Filing targets: SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2026 · first_quarter · 1T
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · 1T
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2026 · first_quarter · 1T
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth. Issues relating to family policy and permitting reform.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth. Issues relating to family policy and permitting reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Tax policy related to qualified business investment tax credit.
Filing targets: SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIDECAR HEALTH via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Consumer-directed health care and transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUERTO RICO DEPARTMENT OF HEALTH via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Appropriations.
Medicare Coverage and Reimbursement. Medicaid Funding.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PMI US CORPORATE SERVICES INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.
Discussions concerning the FY 2026 appropriations bills. Provisions related to FDA regulation of tobacco.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864: HELP Copays Act. General Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Issues related to tariff and trade policy.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
THE ORTHOFORUM via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Tariffs.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
NOMI HEALTH, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General education on Nomi Health. Prior authorization. Issues related to healthcare cost transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NCTA - THE INTERNET & TELEVISION ASSOCIATION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Spectrum. General telecommunications issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
ILLUMINA, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General discussions related to Medicare reimbursement for diagnostic tests.
General discussions related to FDA regulation of diagnostics.
General trade issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MUTUAL OF OMAHA via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Education related to health insurance options.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INSULET CORPORATION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General education on diabetes care. General education about Insulet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENMAB via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General Medicare/Medicaid Issues. 340B Issues.
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FOX CORPORATION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELIXIS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Intellectual property.
Implementation of Inflation Reduction Act of 2022.
Policy to advance pharmaceutical research and development. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.
Alzheimer's Disease. Anti Obesity Medication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DH DIAGNOSTICS LLC via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Issues related to diagnostic testing, antimicrobial resistance, Alzheimers. Oncology/Artificial Intelligence. Hepatitis C Funding. Issues related to tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAREDX, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Drug pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA PHARMACEUTICALS LP via TODD STRATEGY GROUP
2026 · first_quarter · Q1
340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies.
Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act. Prescription drug pricing policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Prostate cancer screening. Women's health.
Prescription drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOLLO GLOBAL MANAGEMENT via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General Education on Apollo Global Management. Insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth. Issues relating to family policy and permitting reform.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth. Issues relating to family policy and permitting reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Prescription drug pricing, including MDRP. Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIAL HEALTH TECHNOLOGY, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
New approach methods. FDA Roadmap.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRUIST FINANCIAL CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
Banking Regulatory Reform Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LYNCH REGENERATIVE MEDICINE, LLC via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
Implementation of draft Medicare Physician Fee Schedule.
Filing targets: HOUSE OF REPRESENTATIVES
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR AMERICA'S PROMISE, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
Social Security and disabled veterans legislation.
Filing targets: SENATE
PFIZER INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to tariff and trade policy. International Supply Chain.
PFIZER INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER INC. via TODD STRATEGY GROUP
2025 · second_quarter · RA
Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy. International Supply Chain.
Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy. International Supply Chain.
Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy. International Supply Chain.
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Tax policy related to qualified business investment tax credit.
Filing targets: SENATE
VIAL HEALTH TECHNOLOGY, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
New approach methods. FDA Roadmap.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRUIST FINANCIAL CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Banking Regulatory Reform Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIDECAR HEALTH via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Consumer-directed health care and transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform, Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOMI HEALTH, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General education on Nomi Health. Prior authorization. Issues related to healthcare cost transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LYNCH REGENERATIVE MEDICINE, LLC via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Implementation of draft Medicare Physician Fee Schedule.
Filing targets: HOUSE OF REPRESENTATIVES
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENMAB via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General Medicare/Medicaid Issues. 340B Issues.
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EXELIXIS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Policy to advance pharmaceutical research and development. 340B.
Implementation of Inflation Reduction Act of 2022.
Intellectual property.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Alzheimer's Disease. Anti Obesity Medication.
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DH DIAGNOSTICS LLC via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Issues related to diagnostic testing, antimicrobial resistance, Alzheimers. Oncology/Artificial Intelligence. HCV Testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAREDX, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
APOLLO GLOBAL MANAGEMENT via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General Education on Apollo Global Management. Insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR AMERICA'S PROMISE, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Social Security and disabled veterans legislation.
Filing targets: SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Rare Disease Issues.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES
PMI US CORPORATE SERVICES INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.
Discussions concerning the FY 2026 appropriations bills. Provisions related to FDA regulation of tobacco.
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General discussions related to FDA regulation of diagnostics.
General discussions related to Medicare reimbursement for diagnostic tests.
General trade issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Drug pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA PHARMACEUTICALS LP via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMGEN INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PUERTO RICO DEPARTMENT OF HEALTH via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare Coverage and Reimbursement. Medicaid Funding.
Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Part D changes. Prescription drug payment reform. 340B issues. Onshoring. S.864 - HELP Copays Act. General Medicare and Medicaid Issues.
Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NETLIST, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
Patent oversight. Intellectual property.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCTA - THE INTERNET & TELEVISION ASSOCIATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Spectrum. General telecommunications issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MUTUAL OF OMAHA via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Education related to health insurance options.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSULET CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General education on diabetes care. General education about Insulet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOX CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Online privacy. Media ownership issues. Streaming issues.
Advertising issues.
Policy issues impacting television and media business. Retransmission consent. Spectrum-related issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariff and trade policy. International Supply Chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Antitrust enforcement and reform. Copyright and content carriage issues.
Corporate tax issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE